Want to see APNHY full AI Analyst Report?
Top Page
Aspen Pharmacare
(OTC:APNHY)
Select Model
Select Model
Rating:68Neutral
Price Target:
$10.50
▲(12.66% Upside)
Action:Reiterated
Date:09/15/26
APNHY scores as moderately attractive, led by improving fundamentals (profit and cash flow rebound plus meaningful de-leveraging) and supportive price trend/momentum. The strong FY2027 guidance and positive management sentiment add upside potential, but the score is capped by the 2026 revenue contraction and a relatively high P/E with a modest dividend yield.
Positive Factors
Deleveraging and net cash
Material deleveraging and a net cash position strengthen Aspen’s financial resilience and reduce interest and refinancing pressure. This gives management greater flexibility to fund manufacturing growth, support commercial expansion, and allocate capital without relying heavily on additional borrowing.
Negative Factors
Revenue contraction and weaker returns
The revenue decline shows that Aspen’s earnings rebound has not yet been matched by durable top-line growth. Lower margins than in earlier years and modest ROE also indicate weaker profit efficiency, which could limit the sustainability of shareholder returns if growth remains subdued.
Read all positive and negative factors
Positive Factors
Negative Factors
Deleveraging and net cash
Material deleveraging and a net cash position strengthen Aspen’s financial resilience and reduce interest and refinancing pressure. This gives management greater flexibility to fund manufacturing growth, support commercial expansion, and allocate capital without relying heavily on additional borrowing.
Read all positive factors
Aspen Pharmacare (APNHY) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$4.35B
Dividend Yield1.27%
Average Volume (3M)0.00
Price to Earnings (P/E)26.4
Beta (1Y)0.17
Revenue Growth-13.45%
EPS GrowthN/A
CountryUS
Employees9,557
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)5.87
Shares Outstanding446,252,320
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-0.08
Price to Book (P/B)0.86
Price to Sales (P/S)2.00
P/FCF Ratio14.78
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.7
Revenue Forecast (FY)$2.31B
Aspen Pharmacare Business Overview & Revenue Model
Company Description
Aspen Pharmacare Holdings Limited, together with its subsidiaries, manufactures and markets specialty and branded pharmaceutical products in Africa, the Middle East, the Americas, Europe CIS, Australasia, and Asia. It operates through Commercial P...
How the Company Makes Money
Aspen Pharmacare makes money primarily by selling pharmaceutical products and by providing pharmaceutical manufacturing services. A key revenue stream is the commercial sale of medicines—Aspen earns revenue when it sells its owned or licensed bran...
Aspen Pharmacare Earnings Call Summary
Earnings Call Date:Sep 02, 2026
(Q4-2026)
| % Change Since: |
Next Earnings Date:Mar 11, 2027
Earnings Call Sentiment Positive
The call was strongly positive. Management highlighted 14% group normalized EBITDA growth, 28% NHEPS growth, ZAR 3.8 billion of free cash flow, a net cash position, successful recovery of the sterile manufacturing business and guidance for at least ZAR 9 billion of EBITDA and more than 50% NHEPS growth in financial year 2027. These positives outweighed the flat group revenue, manufacturing revenue decline, restructuring and impairment charges, geopolitical effects and near-term Canadian GLP-1 API uncertainty.Positive Updates
Commercial Pharma EBITDA Growth
Commercial Pharma delivered 13% EBITDA growth in constant exchange rate, extending double-digit growth from financial year 2025. Growth was supported by organic growth in emerging markets and the China reshape program.
Negative Updates
Flat Group Revenue
Group revenue was flat in constant exchange rate, with Commercial Pharma growth offset by a decline in Manufacturing revenue.
Read all updates
Q4-2026 Updates
Positive
Negative
Commercial Pharma EBITDA Growth
Commercial Pharma delivered 13% EBITDA growth in constant exchange rate, extending double-digit growth from financial year 2025. Growth was supported by organic growth in emerging markets and the China reshape program.
Read all positive updates
Company Guidance
For financial year '27, Aspen expects the commercial pharma base business to grow in mid-single digits, both in revenue and EBITDA, manufacturing revenue growth of greater than 50%, manufacturing EBITDA to more than double financial year '26 EBITDA, and sterile finished dose form EBITDA of ZAR 2.2 billion, with sterile finished dose form achieving positive EBITDA; normalized EBITDA is guided to at least ZAR 9 billion, with the intention to get at least a further ZAR 1.3 billion, implying more than 50% growth in NHEPS, while stronger free cash flow, stable capital investment, sustained working capital focus, tax rates of 24%, 25%, and commencement of GLP-1s will be additive, with a global GLP-1 rollout to contribute substantially not included in this guidance; Mounjaro sales are expected to be more than ZAR 2 billion.Aspen Pharmacare Financial Statement Overview
Summary
Income Statement
58
Neutral
Balance Sheet
73
Positive
Cash Flow
66
Positive
| Breakdown | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 34.14B | 43.36B | 44.71B | 40.71B | 38.61B |
| Gross Profit | 13.76B | 19.13B | 19.42B | 18.41B | 18.31B |
| EBITDA | 7.16B | 2.16B | 9.90B | 10.19B | 9.93B |
| Net Income | 2.59B | -1.08B | 4.40B | 5.23B | 6.49B |
Balance Sheet | |||||
| Total Assets | 107.41B | 135.89B | 139.16B | 134.28B | 111.38B |
| Cash, Cash Equivalents and Short-Term Investments | 15.87B | 6.41B | 12.34B | 10.91B | 6.18B |
| Total Debt | 15.44B | 36.12B | 36.46B | 29.28B | 22.25B |
| Total Liabilities | 27.68B | 51.00B | 54.29B | 48.05B | 40.43B |
| Stockholders Equity | 79.73B | 84.89B | 84.86B | 86.24B | 70.94B |
Cash Flow | |||||
| Free Cash Flow | 4.63B | 104.00M | 690.00M | 2.34B | 2.68B |
| Operating Cash Flow | 6.73B | 5.16B | 6.22B | 5.52B | 5.37B |
| Investing Cash Flow | 23.83B | -5.22B | -9.47B | -3.42B | -2.16B |
| Financing Cash Flow | -20.86B | -162.00M | 3.62B | -420.00M | -4.68B |
Aspen Pharmacare Technical Analysis
Positive
9.32
Price Trends
9.23
Positive
9.02
Positive
8.10
Positive
Market Momentum
0.16
Negative
54.41
Neutral
82.09
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For APNHY, the sentiment is Positive. The current price of 9.32 is below the 20-day moving average (MA) of 9.49, above the 50-day MA of 9.23, and above the 200-day MA of 8.10, indicating a bullish trend. The MACD of 0.16 indicates Negative momentum. The RSI at 54.41 is Neutral, neither overbought nor oversold. The STOCH value of 82.09 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for APNHY.
Aspen Pharmacare Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | $4.35B | 26.39 | 3.28% | 1.27% | -13.45% | ― | |
66 Neutral | $2.38B | 148.70 | 1.43% | ― | -8.81% | -96.21% | |
60 Neutral | $5.50B | 33.47 | -326.75% | ― | 9.28% | 4917.17% | |
54 Neutral | $1.89B | -1.08 | -55.97% | 8.55% | -4.18% | -2138.82% | |
53 Neutral | $2.42B | -21.48 | -10.42% | ― | 24.85% | -264.42% | |
52 Neutral | $1.97B | -8.59 | 76.83% | ― | -12.17% | -365.51% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
APNHY
Aspen Pharmacare
9.67
3.93
68.56%
PRGO
Perrigo Company
13.56
-5.97
-30.56%
SUPN
Supernus Pharmaceuticals
41.28
-2.71
-6.16%
HCM
HUTCHMED
13.79
-3.65
-20.93%
AMRX
Amneal Pharmaceuticals
16.65
6.91
70.94%
ALVO
Alvotech
5.02
-2.94
-36.93%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.